Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Kim (La Jolla, United States of America), R. Channick (Los Angeles, United States of America), K. Chin (Dallas, United States of America), L. Melendres-Groves ( Albuquerque, United States of America), A. Ravichandran ( Indianapolis, United States of America), M. Brand ( Allschwil, Switzerland), M. Flynn (South San Francisco, United States of America), S. Leroy ( Allschwil, Switzerland), A. Morganti ( Allschwil, Switzerland), V. Mclaughlin ( Ann Arbor, United States of America). Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets. 5458

Member's Comments

No comment yet.

Related content which might interest you: Macitentan in portopulmonary hypertension (PoPH): Real-world data from OPUS and OrPHeUS Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Macitentan in incident and prevalent pulmonary arterial hypertension (PAH): OPUS/OrPHeUS real-world data Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Interim analysis of pulmonary arterial hypertension (PAH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Idiopathic pulmonary arterial hypertension in the elderly: Data from the French registry Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Transitioning pulmonary arterial hypertension patients from bosentan to macitentan: efficacy and safety data. Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Source: Eur Respir J 2016; 47: 243-253 Year: 2016 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 PROs: which instruments are available in pulmonary hypertension? Source: Virtual Congress 2020 – Pulmonary vascular diseases Year: 2020 External validation of the REVEAL risk score calculator for PAH survival: A French pulmonary hypertension network analysis Source: Annual Congress 2012 - Pulmonary circulation: clinical databases and registries Year: 2012 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Macitentan in chronic thromboembolic pulmonary hypertension (CTEPH): experience from the OPUS registry Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018